PapersPMID:21502597
A phase II trial of huperzine A in mild to moderate Alzheimer disease.
No finding here moved its endpoint.
What did not
1 findingHow to read these marks →- No detected effect on Alzheimer's Disease Assessment Scale-cognitive subscale (ADAS-cog) score
very limited
“Huperzine A 200 μg BID did not influence change in ADAS-Cog at 16 weeks.”
- Study
- RCT
- Duration
- 4 months
- Dose studied
- huperzine A 200 μg BID, oral
- Population
- Adults with mild to moderate Alzheimer disease; multicenter trial, huperzine A 200 μg BID against placebo
Study record
- Design
- randomised controlled trial
- Species
- human
- Population
- individuals with mild to moderate Alzheimer disease
- Participants
- 210
- Comparator
- placebo
- Duration
- 112 days
- Endpoints measured
- 6